Impact of Galectins in Resistance to Anticancer Therapies.
The Galectin Family as Molecular Targets: Hopes for Defeating Pancreatic Cancer
Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities
Autism-like phenotype and risk gene mRNA deadenylation by CPEB4 mis-splicing.
Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker
Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy
Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk
Increased Plasma Levels of galectin-1 in Pancreatic Cancer: Potential Use as Biomarker
Translational reprogramming in tumor cells can generate oncoselectivity in viral therapies.
A novel translational control mechanism involving RNA structures within coding sequences
Poly(ADP-Ribose) Polymerases: New Players in the Pathogenesis of Exocrine Pancreatic Diseases.
Snail1 is required for the maintenance of the pancreatic acinar phenotype.
The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer.
Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and Angiogenesis in Chronic Liver Disease
Targeting Galectin-1 in pancreatic cancer: immune surveillance on guard.
Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation.
Key contribution of CPEB4-mediated translational control to cancer progression, Nature Medicine
Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer.
Tissue plasminogen activator induces pancreas cancer cell proliferation by a non-catalytic mechanism that requires ERK1/2 activation through Epidermal Growth Factor Receptor and Annexin A2
Tissue plasminogen activator mediates amyloid induced neurotoxicity via sustained Erk1/2 activation.